Department of Psychiatry, KwanDong University College of Medicine, Gyunggi, Korea.
Expert Rev Neurother. 2010 Feb;10(2):275-90. doi: 10.1586/ern.09.148.
The differential effects of serotonin-reuptake inhibitors on obsessive-compulsive disorder (OCD) were sufficient to presume that a serotonin regulatory disorder is the most essential part of the pathophysiology of OCD. In patients with OCD, however, a high-dose of serotonin-reuptake inhibitor monotherapy may not be sufficient, and approximately half of patients were noted to be treatment-resistant. As results from previous studies have shown, there have been positive treatment responses to the dopaminergic antagonists. This suggests that other neurotransmitter systems, such as dopamine, are involved in the pathophysiology of OCD. Preclinical, neuroimaging and neurochemical studies have provided evidence demonstrating that the dopaminergic system is involved in inducing or aggravating the symptoms that are indicative of OCD. In this article, we review the dopaminergic system in OCD pathophysiology as well as reviewing the effect of drugs that act on dopaminergic activity in OCD.
选择性 5-羟色胺再摄取抑制剂对强迫症（OCD）的差异作用足以假定 5-羟色胺调节障碍是 OCD 病理生理学的最重要部分。然而，在 OCD 患者中，高剂量的选择性 5-羟色胺再摄取抑制剂单药治疗可能不够，约有一半的患者被认为是治疗抵抗的。正如先前研究的结果所示，多巴胺能拮抗剂有积极的治疗反应。这表明其他神经递质系统，如多巴胺，也参与 OCD 的病理生理学。临床前、神经影像学和神经化学研究提供了证据，表明多巴胺能系统参与了诱发或加重 OCD 症状。在本文中，我们回顾了 OCD 病理生理学中的多巴胺能系统，以及综述了作用于 OCD 中多巴胺活性的药物的效果。
